LCM
IONS icon

Legato Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Legato Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,840
Closed -$1.49M – 768
2026
Q1 		$1.49M Buy
19,840
+13,685
+222% +$1.08M 0.14% 207
2025
Q4 		$487K Sell
6,155
-11,145
-64% -$839K 0.04% 552
2025
Q3 		$1.13M Buy
+17,300
New +$845K 0.12% 257
2024
Q1 		– Sell
-5,455
Closed -$276K – 593
2023
Q4 		$276K Buy
+5,455
New +$261K 0.04% 502

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Legato Capital Management's IONS Position: Q2 2026 in Review

Legato Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 19,840 shares — an estimated $1.49M sold.

Legato Capital Management first reported a position in IONS in Q4 2023 and held it in 4 quarters. The position peaked at $1.49M in Q1 2026. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Legato Capital Management reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Legato Capital Management sold 19,840 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.49M.
  • Legato Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Legato Capital Management's Ionis Pharmaceuticals position peaked at $1.49M in Q1 2026.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.